United States · 
What does Perseus-Soros Biopharmaceutical Fund invest in?
Perseus-Soros Biopharmaceutical Fund invests most often at Series D and Series C (73% of the rounds on record), in sectors such as Nanotechnology and Video.
Perseus-Soros Biopharmaceutical Fund highlights
- 01
11 rounds on record
- 02
Mostly Series D and Series C: 73% of its rounds
- 03
7 exits from the portfolio
What they do
- Type
- VC firm (from a list, unverified)
- Cheque size
- Not stated
- Sectors
- NanotechnologyVideo
- Based in
- United States
- Cold pitches
- Not stated
The record
Every round we can evidence, newest first11 appearances
- 2007
1 round
- Nov
- 2005
3 rounds
- May
- Apr
- Mar
- 2004
3 rounds
- Aug
- Jul
- Apr
- 2003
3 rounds
- Nov
- Aug
- Jan
- 2002
1 round
- Jan
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
Exits from the portfolio
Companies it backed that were later bought or listed7 in all
Auxilium PharmaceuticalsBought by Endo Health Solutions$2.6BOct 2014
Ambit BiosciencesBought by Daiichi Sankyo$410MSept 2014
SkinMedicaBought by AllerganUndisclosedNov 2012
CardiokineBought by Cornerstone TherapeuticsUndisclosedJan 2012
Aton PharmaBought by Valeant Pharmaceuticals International$318MMay 2010
Auxilium PharmaceuticalsListedUndisclosedDec 2007
MyogenBought by Gilead SciencesUndisclosedOct 2006
An exit counts when it came after the firm's first round in the company. From historical deal records.